The Good, the Bad, and the Best Jobs - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

The Good, the Bad, and the Best Jobs
Readers provide insight into the best companies to work for as well as the ups and downs of their jobs.

Pharmaceutical Technology
Volume 32, Issue 12, pp. 74-73

Worst aspects of jobs

"Lack of acknowledgment by management of my role."

"Constraints of compliance to change."

"Constant state of not knowing how long we will be employed."

"No rewards for going the extra mile," ... "or for discovery."

"Continuously changing internal requirements."

"High work load as many projects are pushed through the pipeline."

"Turnover" ... "and frequent reorganization."

"Waiting for results from universities."

"A dull and redundant work/repeat" and "shift work."

"No appreciation that we're running a global business and need global processes."

"Regulations, regulations, regulations."

"Lulls in the work cycle."

"Having to contract to people who think they know all the answers."

"Regular panic to meet customer deadlines."

"Management does not listen to or adapt new creative ideas."

"I'm stuck in a deadbeat town somewhere in Germany."

"No improvement in quality of products."

"Working across different time zones."

"Frustrations of failed experiments."

"It's hard to see how my daily activities are advancing the larger strategy."

"Slow computer systems," and "old, unreliable equipment."


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
USP Faces New Challenges
Source: Pharmaceutical Technology,
Click here